Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients

Therapeutic Drug Monitoring

Volumn 35, Issue 5, 2013, Pages 624-630

  Teh, Lay Kek ^a   Hamzah, Sharina ^a   Hashim, Hazwanie ^a   Bannur, Zakaria ^a   Zakaria, Zainul Amiruddin ^a,b   Hasbullani, Zakaria ^a   Shia, John Kwong Siew ^a   Fijeraid, Henry ^b   Md Nor, Azmid ^c   Zailani, Mohd ^c   Ramasamy, Prabu ^c   Ngow, Harris ^c   Sood, Suneet ^a   Salleh, Mohd Zaki ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^c INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

5 fluorouracil; adverse effect; dihydropyrimidine dehydrogenase; neutropenia; pharmacogenotypes

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; COUGHING; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIARRHEA; DRUG BLOOD LEVEL; DRUG FEVER; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAND PARESTHESIA; HAND TREMOR; HEMATOMA; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LOSS OF APPETITE; MALE; NAUSEA; NEUTROPENIA; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FLUOROURACIL; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC;

EID: 84885023351     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318290acd2     Document Type: Article

References (23)

1. Findlay MP, Raynaud F, Cunningham D, et al. Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-Alpha. Ann Oncol. 1996;7:47-53
2. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul. 2001;41:151-157
3. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-flurouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2001;7:2832-2839
4. Tsalic M, Bar-Sela G, Beny A, et al. Severe toxicity related to the 5-fluorouracil/leucovorin combination (the mayo clinic regimen). Am Clin Oncol. 2003;26:103-106
5. Meinsma R, Fernandez-Salguero P, van Kuilenburg ABP, et al. Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracil urea. DNA Cell Biol. 1995;14:1-6
6. Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998;51: 391-400
7. van Kuilenburg AB, Klumpen HJ, Westermann AM, et al. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur J Cancer. 2007;43:459-465
8. Kleibl Z, Fidlerova J, Kleiblova P, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma. 2009;56:303-316
9. Kubota T. 5-Fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol. 2003;8:127-131
10. Fredj RB, Gross E, Chouchen L, et al. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. C R Biol. 2007;330:764-769
11. Mattison LK, Fourie J, Hirao Y, et al. The uracil activity: Pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res. 2006;12:549-555
12. Ciccolini J, Mercier C, Evrard A, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28:678-685
13. U.S Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). NHI Publication No. 03-5410, Bethesda, MD, Version 4.0. 2009
14. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry: Bioanalytical Method Validation. Rockville: CDER, 2001 May. Available at: Http:// www.fda.gov/downloads/Drugs/./Guidances/ucm070107.pdf. Accessed on September 18, 2012
15. Duffy M, Crown JA. Personalized approach to cancer treatment: How biomarkers can help. Clin Chem. 2008;54:1770-1779
16. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-3268
17. Grem JL. 5-fluropyrimidines. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles & Practice. Lippincott Williams & Wilkins, Philadelphia; 1996:149-211
18. Lu Z, Zhang R, Diasio RB. Population characteristic of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther. 1995;58: 512-522
19. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasians individuals. Clin Cancer Res. 2005;11:5886-5892
20. Morel A, Boisdron-Celle MB, Fey L, et al. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem. 2006;40:11-17
21. Kristensen MH, Pedersen PL, Melsen GV, et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Intern Med Res. 2010;38:870-883
22. van Kuilenbur ABP, Meinsma R, Zoetekouw L, et al. High prevalence of the IVS14 + 1G.A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-Associated toxicity. Pharmacogenetics. 2002;12:555-558
23. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-Threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4:181-189